Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure

Aim. To investigate clinical efficacy of nebivolol and metoprolol in the complex treatment of patients with coronary heart disease (CHD) and II-III functional class chronic heart failure (CHF). Material and methods. The study involved 110 patients with CHD and CHF, functional class II-III, by NYHA c...

Full description

Saved in:
Bibliographic Details
Main Authors: A. G. Evdokimova, A. E. Radzevich, O. I. Tereshchenko, E. V. Kovalenko
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2005-04-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/931
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849699467600592896
author A. G. Evdokimova
A. E. Radzevich
O. I. Tereshchenko
E. V. Kovalenko
author_facet A. G. Evdokimova
A. E. Radzevich
O. I. Tereshchenko
E. V. Kovalenko
author_sort A. G. Evdokimova
collection DOAJ
description Aim. To investigate clinical efficacy of nebivolol and metoprolol in the complex treatment of patients with coronary heart disease (CHD) and II-III functional class chronic heart failure (CHF). Material and methods. The study involved 110 patients with CHD and CHF, functional class II-III, by NYHA classification. All participants, aged 47-79 years, had ejection fraction <45%. The patients were divided into three groups. Group I (n=38) received nebivolol (2.5-5 mg/d) plus standard therapy; Group II (n=36) – metoprolol tartrate (50-100 mg/d) plus standard therapy; Group III (n=36) – only standard therapy. During 4-month followup, the following parameters were assessed: clinical efficacy, physical stress tolerance (PST), quality of life (QoL), number and duration of silent myocardial ischemia episodes (SMIE), left ventricular (LV) structural, functional and hemodynamic parameters, blood rheology, platelet aggregation, and lipid profile. Results. At baseline, no significant decrease of LV total contractility was observed. Four month later, in all treatment groups PST increased, number and duration of SMIE reduced, patients’ condition, central hemodynamics and LV remodeling parameters improved, as well as lipid profile, blood rheology and platelet hemostasis. Positive dynamics was greater in nebivolol group. Conclusion. In complex treatment of patients with CHD and CHF, nebivolol acts similar to metoprolol. Nebivolol increased treatment efficacy, increased PST, reduced number and duration of SMIE, prevented LVH progression, improved clinical status, QoL, lipid profile, platelet hemostasis, blood rheology.
format Article
id doaj-art-f77af8ef2dca45b6a4da8c24da9bedaf
institution DOAJ
issn 1728-8800
2619-0125
language Russian
publishDate 2005-04-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-f77af8ef2dca45b6a4da8c24da9bedaf2025-08-20T03:18:34Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-04-01425259646Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failureA. G. Evdokimova0A. E. Radzevich1O. I. Tereshchenko2E. V. Kovalenko3Moscow State Medico-Stomatological University, MoscowMoscow State Medico-Stomatological University, MoscowMoscow State Medico-Stomatological University, MoscowMoscow State Medico-Stomatological University, MoscowAim. To investigate clinical efficacy of nebivolol and metoprolol in the complex treatment of patients with coronary heart disease (CHD) and II-III functional class chronic heart failure (CHF). Material and methods. The study involved 110 patients with CHD and CHF, functional class II-III, by NYHA classification. All participants, aged 47-79 years, had ejection fraction <45%. The patients were divided into three groups. Group I (n=38) received nebivolol (2.5-5 mg/d) plus standard therapy; Group II (n=36) – metoprolol tartrate (50-100 mg/d) plus standard therapy; Group III (n=36) – only standard therapy. During 4-month followup, the following parameters were assessed: clinical efficacy, physical stress tolerance (PST), quality of life (QoL), number and duration of silent myocardial ischemia episodes (SMIE), left ventricular (LV) structural, functional and hemodynamic parameters, blood rheology, platelet aggregation, and lipid profile. Results. At baseline, no significant decrease of LV total contractility was observed. Four month later, in all treatment groups PST increased, number and duration of SMIE reduced, patients’ condition, central hemodynamics and LV remodeling parameters improved, as well as lipid profile, blood rheology and platelet hemostasis. Positive dynamics was greater in nebivolol group. Conclusion. In complex treatment of patients with CHD and CHF, nebivolol acts similar to metoprolol. Nebivolol increased treatment efficacy, increased PST, reduced number and duration of SMIE, prevented LVH progression, improved clinical status, QoL, lipid profile, platelet hemostasis, blood rheology.https://cardiovascular.elpub.ru/jour/article/view/931coronary heart diseasechronic heart failurehemodynamicsremodelingnebivololmetoprolol
spellingShingle A. G. Evdokimova
A. E. Radzevich
O. I. Tereshchenko
E. V. Kovalenko
Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
Кардиоваскулярная терапия и профилактика
coronary heart disease
chronic heart failure
hemodynamics
remodeling
nebivolol
metoprolol
title Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
title_full Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
title_fullStr Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
title_full_unstemmed Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
title_short Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
title_sort clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and ii iii functional class chronic heart failure
topic coronary heart disease
chronic heart failure
hemodynamics
remodeling
nebivolol
metoprolol
url https://cardiovascular.elpub.ru/jour/article/view/931
work_keys_str_mv AT agevdokimova clinicalefficacyofnebivololandmetoprololincomplextreatmentofpatientswithcoronaryheartdiseaseandiiiiifunctionalclasschronicheartfailure
AT aeradzevich clinicalefficacyofnebivololandmetoprololincomplextreatmentofpatientswithcoronaryheartdiseaseandiiiiifunctionalclasschronicheartfailure
AT oitereshchenko clinicalefficacyofnebivololandmetoprololincomplextreatmentofpatientswithcoronaryheartdiseaseandiiiiifunctionalclasschronicheartfailure
AT evkovalenko clinicalefficacyofnebivololandmetoprololincomplextreatmentofpatientswithcoronaryheartdiseaseandiiiiifunctionalclasschronicheartfailure